



Learn about QuantiFERON[®]-TB Gold Plus from the experts

The WHO now recommends systematic testing and treatment of latent TB infection – and universally supports modern blood tests for patients at risk (1).

It's time to move on from the skin test and join the TB testing revolution with QuantiFERON-TB Gold Plus.

- More practical
- More accurate
- More cost-effective

Dr. Delia Goletti is head of the Translational Research Unit at Italy's National Institute for Infectious Diseases (INMI), where her research has played an important role in the development of QuantiFERON-TB Gold Plus.

Sample to Insight



Is screening and treatment of latent TB the key to TB elimination?

Tuberculosis continues to threaten the lives of people worldwide as each year 10 million people develop this disease.

Join **Dr. Jean-Pierre Zellweger** as he discusses the 2019 WHO global TB report, new preventive treatment regimens and the benefits of using QuantiFERON-TB Gold Plus as a primary screening method to help reach the End TB Strategy targets. Dr. Jean-Pierre Zellweger is a former chief of the TB clinic at the University Hospital in Lausanne.



View this webinar at
go.qiagen.com/WHOupdate



QuantiFERON-TB Gold Plus: Is your practice up-to-date?

QFT®-Plus features innovative CD8 T cell technology that provides clinicians with a more comprehensive picture of a patient's immune response to TB. Recent publications illustrate the benefits of QFT-Plus technology for at-risk patient populations – including in contact investigation, healthcare worker screening and immunocompromised patients.

Join **Dr. Masae Kawamura** for a discussion of the latest scientific advancements in TB testing, including a review of recent publications and a discussion of case scenarios applying the insights of QFT-Plus. Dr. Kawamura is a former TB Controller and Senior Director of Scientific and Medical Affairs for TB diagnostics, QIAGEN.



View this webinar at
go.qiagen.com/QFTplusMasaewebinarROW



Advancing healthcare provider TB testing with QuantiFERON-TB Gold Plus

Healthcare providers (HCPs) are at increased risk for TB infection and can benefit from systematic testing and treatment of latent TB infection. Over the past 15 years, laboratory-based TB interferon gamma release assays (IGRAs) have been transforming screening programs with higher accuracy, operational advantages and convenience.

Join **Dr. Masae Kawamura**, as she provides an overview of the standard policies and practices of screening HCPs for TB infection. She will also discuss new preventive treatment regimens, the use of IGRAs as a primary screening method and the benefits of QuantiFERON-TB Gold Plus.



View this webinar at
go.qiagen.com/HCPrecording

Latent tuberculosis infection in children

The latest WHO guidelines strongly recommend diagnosis and treatment of latent TB infection for children age <5 years who are household contacts of active TB cases.

Join **Pr. Christophe Delacourt** to learn more about TB testing in pediatrics. Pr. Delacourt will describe pediatric TB testing guidelines for the WHO, discuss clinical best practices, and provide an up-to-date review of the latest research in latent TB testing options. Pr. Delacourt is a pediatrician and head of the Pediatric Pulmonology ward at the Necker Enfants Malades Hospital in Paris. He is also president of the French Pediatrics Society.



View this webinar at
go.qiagen.com/Pediatrics-Recording

Insights on the development of a national health plan for TB

In 2018, the WHO updated its guidelines on the management of TB to include expanded screening of at-risk populations for latent TB infection (LTBI). Migrants are at increased risk for latent and active tuberculosis, and screening for LTBI is a critical component of a TB prevention and control strategy.

Join **Dr. Eskild Petersen** as he discusses the challenges of TB control and the WHO goal of global elimination. Topics include migrant screening, international guidelines and policies, the use of IGRA blood tests and the identification of at-risk populations. Dr. Petersen is an international expert in infectious diseases tasked with designing a National Health Plan for the Sultanate of Oman.



View this webinar at
go.qiagen.com/MigrantsRecording

Protecting students from TB

Active TB investigations are a common, costly occurrence. People living in dense housing arrangements – such as college dormitories – are at significantly increased risk of TB infection.

Join **Dr. Sonia Qasba** as she describes recent TB exposures at US colleges, testing recommendations from the ACHA and the CDC, and how modern TB blood tests can improve the effectiveness and efficiency of college screening programs. Dr. Sonia Qasba is a practicing physician at Suburban Hospital, a part of Johns Hopkins Medicine. She is Board-certified in infectious disease, internal medicine, and pediatrics.



View this webinar at
go.qiagen.com/studentrecordinguk



View this webinar at
go.qiagen.com/HIV-recording

Management of TB infection in HIV co-infected patients

People living with HIV are at increased risk for TB, and reliable surveillance is critical to protect their health. In their 2018 guidelines, the WHO expanded existing recommendations to include latent tuberculosis testing and treatment for all persons living with HIV – regardless of country incidence or income.

Join **Dr. Delia Goletti** to learn more about TB testing in patients living with HIV using QuantiFERON-TB Gold Plus. Topics include a review of published data and a discussion of the frontiers of TB diagnostic research, including untapped markers for latent TB infection and new therapeutic strategies to treat the disease. Dr. Delia Goletti is head of the Translational Research Unit at Italy's National Institute for Infectious Diseases (INMI), and her research has played an important role in development of QuantiFERON-TB Gold Plus.



View this webinar at
go.qiagen.com/OccupationalHealth

Occupational health screening for latent tuberculosis: an update

The occupational health setting carries unique risks for TB infection and latent TB reactivation.

Join **Dr. Manish Pareek** as he provides an overview of best practices for screening HCPs for TB infection, describes current global testing guidelines and provides a UK-specific perspective on TB screening in low-burden settings. Dr. Pareek will also discuss the performance and cost-effectiveness of modern TB blood tests (IGRAs). Dr. Pareek is an Associate Clinical Professor in Infectious Diseases at the University of Leicester.

Ready to learn more? Talk to your local QuantiFERON sales representative, or visit www.QuantiFERON.com.

References:

1. WHO. (2018) Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management. WHO/CDS/TB/2018.4.

QFT-Plus is an in vitro diagnostic aid for detection of *Mycobacterium tuberculosis* infection. QFT-Plus is an indirect test for *M. tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus package inserts, up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

Trademarks: QIAGEN®, Sample to Insight®, QuantiFERON®, QFT® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

PROM-14853-002 1123582 01/2021 © 2021, QIAGEN, all rights reserved.

Ordering www.qiagen.com/shop | Technical Support support.qiagen.com | Website www.QuantiFERON.com